<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818662</url>
  </required_header>
  <id_info>
    <org_study_id>160701</org_study_id>
    <nct_id>NCT00818662</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Two Dose Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Disease Cooperative Study (ADCS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the efficacy and safety of 2 doses of Immune
      Globulin Intravenous (IGIV), 10% administered every 2 weeks as an intravenous (IV) infusion
      compared with placebo in participants with mild to moderate Alzheimer's disease (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study visits: Each participant will be tested at the investigational site, and if qualified,
      will be treated intravenously (through a vein) every two weeks for 70 weeks (approximately 18
      months). The first three infusions must be done at the site, but if the infusions are well
      tolerated, subsequent infusions may be done by a qualified healthcare provider in the home or
      other suitable location. Each participant must return to the site every 3 months for
      evaluation of cognition as well as blood tests and scans of the brain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</measure>
    <time_frame>Baseline &amp; 18 months</time_frame>
    <description>The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site.
Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>Baseline &amp; 18 Months</time_frame>
    <description>The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner.
Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</measure>
    <time_frame>Baseline &amp; 9 months</time_frame>
    <description>The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site.
Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>Baseline &amp; 9 Months</time_frame>
    <description>The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner.
Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 9 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment</measure>
    <time_frame>Baseline &amp; 9 Months</time_frame>
    <description>The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating.
A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).
Very much better
Much better
A little better
Same
A little worse
Much worse
Very much worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 18 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment</measure>
    <time_frame>Baseline &amp; 18 Months</time_frame>
    <description>The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating.
A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).
Very much better
Much better
A little better
Same
A little worse
Much worse
Very much worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination</measure>
    <time_frame>Baseline &amp; 18 months</time_frame>
    <description>The 3MS is a comprehensive validated instrument that provides a 100 point composite rating for spatial and temporal orientation, verbal recall, simple attention, working memory, naming, repetition, comprehension, writing and constructional abilities. Scores range from 0 to 100 with lower values indicating greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment</measure>
    <time_frame>Baseline &amp; 18 months</time_frame>
    <description>The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 12 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response</measure>
    <time_frame>Baseline &amp; 18 months</time_frame>
    <description>The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response</measure>
    <time_frame>Baseline &amp; 18 months</time_frame>
    <description>The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward</measure>
    <time_frame>Baseline &amp; 18 months</time_frame>
    <description>This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward</measure>
    <time_frame>Baseline &amp; 18 months</time_frame>
    <description>This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency</measure>
    <time_frame>Baseline &amp; 18 months</time_frame>
    <description>In the FAS assessment of phenomic verbal fluency, participants are given 1 minute each to name as many words as they can that begin with a specified letter (F, A, S). To receive credit, words must be verifiable in a dictionary, cannot be proper nouns, and cannot be the same word or variations of the same word (e.g., the same word with a different ending, such as 'acts,' 'acted,' 'acting'). Results are presented as total number correct; therefore, lower numbers indicate greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution</measure>
    <time_frame>Baseline &amp; 18 months</time_frame>
    <description>WAIS-R digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a 'key,' which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency</measure>
    <time_frame>Baseline &amp; 18 months</time_frame>
    <description>In this test, which assesses semantic verbal fluency, participants are given 1 minute to name as many items in the category &quot;animals&quot; as possible. To receive credit that word cannot be a mythical animal, but can be an animal species; breed; male, female, or infant name for a species (e.g., bull, cow, calf); in addition, names for birds, fish, reptiles, and insects receive credit. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A</measure>
    <time_frame>Baseline &amp; 18 months</time_frame>
    <description>This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,…). Total values for TMT Part A range between 0 and 150 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B</measure>
    <time_frame>Baseline &amp; 18 months</time_frame>
    <description>This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,…). Total values for TMT Part B range between 0 and 300 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test</measure>
    <time_frame>Baseline &amp; 18 months</time_frame>
    <description>In this test, which assesses constructional ability, visuoperception, and executive functioning, the participant is given a blank sheet of paper and asked to draw the face of a clock showing the numbers and 2 hands set to 'ten after eleven.' Results are presented as score obtained (range 0 to 5, with 0 indicating the greatest impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Study Product-related Non-serious Adverse Events (Non-SAEs), by System Organ Class</measure>
    <time_frame>Throughout the study period, approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Study Product-related Serious Adverse Events (SAEs), by System Organ Class</measure>
    <time_frame>Throughout the study period, approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Any Non-serious Adverse Events (Non-SAEs), by System Organ Class</measure>
    <time_frame>Throughout the study period, approximately 4 years</time_frame>
    <description>Related and unrelated non-SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Any Serious Adverse Events (SAEs), by System Organ Class</measure>
    <time_frame>Throughout the study period, approximately 4 years</time_frame>
    <description>Related and unrelated SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)</measure>
    <time_frame>During or within 72 hours of completion of an infusion</time_frame>
    <description>Refers to non-SAEs and/or SAEs occurring during infusion or within 72 hours of completion of infusion (regardless of causality)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)</measure>
    <time_frame>Throughout the study period, approximately 4 years</time_frame>
    <description>Each adverse event (AE) that was considered related to investigational product (IP) was linked to the most recent infusion administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE)</measure>
    <time_frame>Throughout each infusion period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (&gt;1.5 g/dL) Between Consecutive Visits</measure>
    <time_frame>Throughout the study period, approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing a Clinically Significant Rash</measure>
    <time_frame>Throughout the study period, approximately 4 years</time_frame>
    <description>Participants requiring systemic therapy or discontinuation from further treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">390</enrollment>
  <condition>Alzheimer´s Disease</condition>
  <arm_group>
    <arm_group_label>IGIV, 10% 400mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGIV, 10% 200mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Human Albumin 0.25% Solution - 4 mL/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.25% human albumin solution infused at 4 mL/kg/2weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Human Albumin 0.25% Solution - 2 mL/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.25% human albumin solution infused at 2 mL/kg/2weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg</intervention_name>
    <description>400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
    <arm_group_label>IGIV, 10% 400mg/kg</arm_group_label>
    <other_name>Gammagard Liquid</other_name>
    <other_name>KIOVIG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg</intervention_name>
    <description>200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
    <arm_group_label>IGIV, 10% 200mg/kg</arm_group_label>
    <other_name>Gammagard Liquid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo solution: Human Albumin 0.25% - 4 mL/kg</intervention_name>
    <description>Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks</description>
    <arm_group_label>Human Albumin 0.25% Solution - 4 mL/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo solution: Human Albumin 0.25% - 2 mL/kg</intervention_name>
    <description>Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks</description>
    <arm_group_label>Human Albumin 0.25% Solution - 2 mL/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Written informed consent - participant (or participant´s legally acceptable
             representative) and caregiver who are willing and able to participate for the duration
             of the study

          -  Diagnosis of probable Alzheimer´s Disease (AD)

          -  Dementia of mild to moderate severity defined as mini-mental state examination (MMSE)
             16-26 inclusive at the time of screening

          -  Neuroimaging (computed tomography [CT] or MRI) performed after symptom onset
             consistent with AD diagnosis

          -  Ability to comply with testing and infusion regimen, including fluency in English or
             Spanish, adequate corrected visual acuity and hearing ability

          -  On stable doses of regulatory authority approved AD medication(s) for at least 3
             months prior to screening. These medications must be continued throughout this study.

          -  If receiving psychoactive medications (e.g. antidepressants other than monoamine
             oxidase inhibitors (MAOIs) and most tricyclics, antipsychotics, anxiolytics,
             anticonvulsants, mood stabilizers, etc), must be on stable doses for at least 6 weeks
             prior to screening

        Main Exclusion Criteria (Reasons why it might not be appropriate to participate):

          -  Any other forms of dementia

          -  Medical issues that might increase the risk of treatment with IGIV, 10%, such as:

               1. Significant problems with blood pressure, heart disease, clotting disorders,
                  strokes or recent heart attacks

               2. Evidence of current bleeding in the brain by MRI

               3. Serious problems with the liver or kidneys

               4. Allergies to blood products

          -  Medical issues that might interfere with the evaluation of the treatment of dementia
             or might make dementia worse, such as:

               1. Diabetes

               2. Recent treatment with chemotherapy or immune suppression

               3. The recent use of other investigational drugs, especially antibody therapy for AD

               4. Severe headaches or psychiatric problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Relkin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alzheimer's Disease Cooperative Study (ADCS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Gelmont, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paw Paw</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Relkin N, Gessert D, Stokes K, Adamiak B, Ngo LY, Thomas R, Gelmont D, Aisen P. The Gammaglobulin Alzheimer Partnership Study (GAP): Design, screening, enrollment and futility analysis results. Alzheimer's &amp; Dementia: The Journal of the Alzheimer's Association 8[4 Suppl], P456. 2012.</citation>
  </reference>
  <reference>
    <citation>Ngo L, Adamiak B, Gelmont D. A confirmatory phase 3 randomized, double-blind, placebo-controlled study of the safety and effectiveness of immune globulin intravenous (human), 10% solution (Gammagard Liquid/Kiovig) for the treatment of mild to moderate Alzheimer's Disease. Poster Presentation: Alzheimer's Association International Conference on Alzheimer's Disease (ICAD), Paris, France July 16-21 2011.</citation>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2009</study_first_posted>
  <results_first_submitted>June 27, 2014</results_first_submitted>
  <results_first_submitted_qc>October 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2014</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer´s</keyword>
  <keyword>Dementia</keyword>
  <keyword>Dementia of Alzheimer Type</keyword>
  <keyword>Immunoglobulins</keyword>
  <keyword>Gammaglobulins</keyword>
  <keyword>Immune Globulin Intravenous (IGIV)</keyword>
  <keyword>Intravenous Immune Globulin (IVIG)</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Amyloid</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was conducted in the U.S., and Canada, at 45 study sites. The first participant was enrolled in December 2008.</recruitment_details>
      <pre_assignment_details>702 participants were enrolled; 308 were screen failures; 4 were discontinued before randomization; and 7 were withdrawn after randomization, but prior to receiving investigational product. Therefore 383 participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IGIV, 10% 400mg/kg</title>
          <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
        </group>
        <group group_id="P2">
          <title>IGIV, 10% 200mg/kg</title>
          <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo 4 mL/kg</title>
          <description>0.25% human albumin solution infused at 4 mL/kg/2weeks
Placebo solution: 4 mL/kg : 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo 2 mL/kg</title>
          <description>0.25% human albumin solution infused at 2 mL/kg/2weeks
Placebo solution: 2 mL/kg : 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unwilling or Unable to Participate</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requires a Prohibited Medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Safety Risk</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Partner Unwilling or Unable</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant's health declined</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Caregiver to pursue other treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moving out of state</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Declined move to another study site</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in living situation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study partner decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Admitted to long term nursing care</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IGIV, 10% 400mg/kg</title>
          <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
        </group>
        <group group_id="B2">
          <title>IGIV, 10% 200mg/kg</title>
          <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo 4 mL/kg</title>
          <description>0.25% human albumin solution infused at 4 mL/kg/2weeks
Placebo solution: 4 mL/kg : 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo 2 mL/kg</title>
          <description>0.25% human albumin solution infused at 2 mL/kg/2weeks
Placebo solution: 2 mL/kg : 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="135"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="63"/>
            <count group_id="B5" value="383"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.5" spread="9.6"/>
                    <measurement group_id="B2" value="70.1" spread="8.3"/>
                    <measurement group_id="B3" value="70.3" spread="9.7"/>
                    <measurement group_id="B4" value="70.1" spread="10.3"/>
                    <measurement group_id="B5" value="70.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</title>
        <description>The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer’s Disease Cooperative Study (ADCS) at each site.
Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.</description>
        <time_frame>Baseline &amp; 18 months</time_frame>
        <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution
Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</title>
          <description>The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer’s Disease Cooperative Study (ADCS) at each site.
Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.</description>
          <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="7.95"/>
                    <measurement group_id="O2" value="8.9" spread="8.20"/>
                    <measurement group_id="O3" value="8.4" spread="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.476</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Results combined from 100 imputations from estimates &amp; standard errors from 100 ANCOVA results for fixed effect of treatment, E4 allele of apolipoprotein E carrier status, &amp; continuous covariates age at baseline, baseline ADAS-Cog &amp; education level</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.530</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Results combined from 100 imputations from estimates &amp; standard errors from 100 ANCOVA results for fixed effect of treatment, E4 allele of apolipoprotein E carrier status, &amp; continuous covariates age at baseline, baseline ADAS-Cog &amp; education level</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</title>
        <description>The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner.
Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.</description>
        <time_frame>Baseline &amp; 18 Months</time_frame>
        <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</title>
          <description>The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner.
Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.</description>
          <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="10.49"/>
                    <measurement group_id="O2" value="-12.4" spread="11.41"/>
                    <measurement group_id="O3" value="-11.4" spread="12.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.812</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
            <estimate_desc>Results combined from 100 imputations from estimates &amp; standard errors from 100 ANCOVA results for fixed effect of treatment, E4 allele of apolipoprotein E carrier status, &amp; continuous covariates age at baseline, baseline ADAS-Cog &amp; education level</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.602</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
            <estimate_desc>Results combined from 100 imputations from estimates &amp; standard errors from 100 ANCOVA results for fixed effect of treatment, E4 allele of apolipoprotein E carrier status, &amp; continuous covariates age at baseline, baseline ADAS-Cog &amp; education level</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</title>
        <description>The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site.
Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.</description>
        <time_frame>Baseline &amp; 9 months</time_frame>
        <population>Intent-to-Treat Analysis Set with both baseline and month 9 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution
Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</title>
          <description>The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site.
Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.</description>
          <population>Intent-to-Treat Analysis Set with both baseline and month 9 assessments.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="5.20"/>
                    <measurement group_id="O2" value="4.5" spread="6.16"/>
                    <measurement group_id="O3" value="3.5" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.368</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
            <estimate_desc>Estimated within a ANCOVA model accounting for the fixed effect of treatment, E4 allele of apolipoprotein E carrier status, and for the continuous covariates age at baseline, baseline ADAS-Cog and education level (in years)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.319</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>Estimated within a ANCOVA model accounting for the fixed effect of treatment, E4 allele of apolipoprotein E carrier status, and for the continuous covariates age at baseline, baseline ADAS-Cog and education level (in years)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</title>
        <description>The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner.
Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.</description>
        <time_frame>Baseline &amp; 9 Months</time_frame>
        <population>Intent-to-Treat Analysis Set with both baseline and month 9 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</title>
          <description>The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner.
Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.</description>
          <population>Intent-to-Treat Analysis Set with both baseline and month 9 assessments.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="7.03"/>
                    <measurement group_id="O2" value="-6.1" spread="8.13"/>
                    <measurement group_id="O3" value="-5.8" spread="8.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.778</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>Estimated within a ANCOVA model accounting for the fixed effect of treatment, E4 allele of apolipoprotein E carrier status, and for the continuous covariates age at baseline, baseline ADCS-ADL and education level (in years)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.851</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
            <estimate_desc>Estimated within a ANCOVA model accounting for the fixed effect of treatment, E4 allele of apolipoprotein E carrier status, and for the continuous covariates age at baseline, baseline ADCS-ADL and education level (in years)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 9 Months in Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment</title>
        <description>The ADCS-CGIC is a validated categorical measure of change in a participant’s clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating.
A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).
Very much better
Much better
A little better
Same
A little worse
Much worse
Very much worse</description>
        <time_frame>Baseline &amp; 9 Months</time_frame>
        <population>Intent-to-Treat Analysis Set with both baseline and month 9 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 9 Months in Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment</title>
          <description>The ADCS-CGIC is a validated categorical measure of change in a participant’s clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating.
A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).
Very much better
Much better
A little better
Same
A little worse
Much worse
Very much worse</description>
          <population>Intent-to-Treat Analysis Set with both baseline and month 9 assessments.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9: Very much better (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: Much better (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: A little better (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: Same (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: A little worse (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: Much worse (6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: Very much worse (7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.306</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 18 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment</title>
        <description>The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating.
A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).
Very much better
Much better
A little better
Same
A little worse
Much worse
Very much worse</description>
        <time_frame>Baseline &amp; 18 Months</time_frame>
        <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment</title>
          <description>The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating.
A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).
Very much better
Much better
A little better
Same
A little worse
Much worse
Very much worse</description>
          <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 18: Very much better (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: Much better (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: A little better (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: Same (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: A little worse (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: Much worse (6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18: Very much worse (7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.660</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.766</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination</title>
        <description>The 3MS is a comprehensive validated instrument that provides a 100 point composite rating for spatial and temporal orientation, verbal recall, simple attention, working memory, naming, repetition, comprehension, writing and constructional abilities. Scores range from 0 to 100 with lower values indicating greater impairment.</description>
        <time_frame>Baseline &amp; 18 months</time_frame>
        <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination</title>
          <description>The 3MS is a comprehensive validated instrument that provides a 100 point composite rating for spatial and temporal orientation, verbal recall, simple attention, working memory, naming, repetition, comprehension, writing and constructional abilities. Scores range from 0 to 100 with lower values indicating greater impairment.</description>
          <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" spread="13.12"/>
                    <measurement group_id="O2" value="-15.3" spread="12.76"/>
                    <measurement group_id="O3" value="-13.5" spread="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.206</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.331</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment</title>
        <description>The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 12 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.</description>
        <time_frame>Baseline &amp; 18 months</time_frame>
        <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment</title>
          <description>The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 12 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.</description>
          <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="12.93"/>
                    <measurement group_id="O2" value="4.9" spread="13.30"/>
                    <measurement group_id="O3" value="2.4" spread="10.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.640</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.075</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response</title>
        <description>The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant’s quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.</description>
        <time_frame>Baseline &amp; 18 months</time_frame>
        <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response</title>
          <description>The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant’s quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.</description>
          <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="5.34"/>
                    <measurement group_id="O2" value="-0.7" spread="4.40"/>
                    <measurement group_id="O3" value="-1.5" spread="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.093</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.094</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response</title>
        <description>The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.</description>
        <time_frame>Baseline &amp; 18 months</time_frame>
        <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response</title>
          <description>The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.</description>
          <population>Intent-to-Treat Analysis Set with both baseline and month 18 assessments.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="4.97"/>
                    <measurement group_id="O2" value="-2.5" spread="5.17"/>
                    <measurement group_id="O3" value="-1.6" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.123</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward</title>
        <description>This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.</description>
        <time_frame>Baseline &amp; 18 months</time_frame>
        <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward</title>
          <description>This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.</description>
          <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
          <units>correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.00"/>
                    <measurement group_id="O2" value="-1.2" spread="2.21"/>
                    <measurement group_id="O3" value="-1.1" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.167</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.998</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward</title>
        <description>This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.</description>
        <time_frame>Baseline &amp; 18 months</time_frame>
        <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward</title>
          <description>This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.</description>
          <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
          <units>correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.95"/>
                    <measurement group_id="O2" value="-1.2" spread="1.88"/>
                    <measurement group_id="O3" value="-1.2" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.173</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.744</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency</title>
        <description>In the FAS assessment of phenomic verbal fluency, participants are given 1 minute each to name as many words as they can that begin with a specified letter (F, A, S). To receive credit, words must be verifiable in a dictionary, cannot be proper nouns, and cannot be the same word or variations of the same word (e.g., the same word with a different ending, such as ‘acts,’ ‘acted,’ ‘acting’). Results are presented as total number correct; therefore, lower numbers indicate greater impairment.</description>
        <time_frame>Baseline &amp; 18 months</time_frame>
        <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency</title>
          <description>In the FAS assessment of phenomic verbal fluency, participants are given 1 minute each to name as many words as they can that begin with a specified letter (F, A, S). To receive credit, words must be verifiable in a dictionary, cannot be proper nouns, and cannot be the same word or variations of the same word (e.g., the same word with a different ending, such as ‘acts,’ ‘acted,’ ‘acting’). Results are presented as total number correct; therefore, lower numbers indicate greater impairment.</description>
          <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
          <units>correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="8.60"/>
                    <measurement group_id="O2" value="-7.4" spread="9.00"/>
                    <measurement group_id="O3" value="-6.3" spread="8.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.238</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.400</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution</title>
        <description>WAIS–R digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a ‘key,’ which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.</description>
        <time_frame>Baseline &amp; 18 months</time_frame>
        <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution</title>
          <description>WAIS–R digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a ‘key,’ which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.</description>
          <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
          <units>correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="10.61"/>
                    <measurement group_id="O2" value="-7.7" spread="9.67"/>
                    <measurement group_id="O3" value="-6.2" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.695</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.410</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency</title>
        <description>In this test, which assesses semantic verbal fluency, participants are given 1 minute to name as many items in the category “animals” as possible. To receive credit that word cannot be a mythical animal, but can be an animal species; breed; male, female, or infant name for a species (e.g., bull, cow, calf); in addition, names for birds, fish, reptiles, and insects receive credit. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.</description>
        <time_frame>Baseline &amp; 18 months</time_frame>
        <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency</title>
          <description>In this test, which assesses semantic verbal fluency, participants are given 1 minute to name as many items in the category “animals” as possible. To receive credit that word cannot be a mythical animal, but can be an animal species; breed; male, female, or infant name for a species (e.g., bull, cow, calf); in addition, names for birds, fish, reptiles, and insects receive credit. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.</description>
          <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
          <units>correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="4.06"/>
                    <measurement group_id="O2" value="-2.2" spread="6.84"/>
                    <measurement group_id="O3" value="-2.7" spread="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.988</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.555</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A</title>
        <description>This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,…). Total values for TMT Part A range between 0 and 150 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.</description>
        <time_frame>Baseline &amp; 18 months</time_frame>
        <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A</title>
          <description>This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,…). Total values for TMT Part A range between 0 and 150 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.</description>
          <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="36.93"/>
                    <measurement group_id="O2" value="20.5" spread="30.61"/>
                    <measurement group_id="O3" value="21.3" spread="35.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.783</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.2</ci_lower_limit>
            <ci_upper_limit>9.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.700</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.1</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B</title>
        <description>This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,…). Total values for TMT Part B range between 0 and 300 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.</description>
        <time_frame>Baseline &amp; 18 months</time_frame>
        <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B</title>
          <description>This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,…). Total values for TMT Part B range between 0 and 300 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.</description>
          <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="60.49"/>
                    <measurement group_id="O2" value="28.4" spread="65.01"/>
                    <measurement group_id="O3" value="31.9" spread="66.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.191</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-15.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-38.0</ci_lower_limit>
            <ci_upper_limit>7.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.892</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-25.4</ci_lower_limit>
            <ci_upper_limit>22.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test</title>
        <description>In this test, which assesses constructional ability, visuoperception, and executive functioning, the participant is given a blank sheet of paper and asked to draw the face of a clock showing the numbers and 2 hands set to ‘ten after eleven.’ Results are presented as score obtained (range 0 to 5, with 0 indicating the greatest impairment).</description>
        <time_frame>Baseline &amp; 18 months</time_frame>
        <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test</title>
          <description>In this test, which assesses constructional ability, visuoperception, and executive functioning, the participant is given a blank sheet of paper and asked to draw the face of a clock showing the numbers and 2 hands set to ‘ten after eleven.’ Results are presented as score obtained (range 0 to 5, with 0 indicating the greatest impairment).</description>
          <population>Per-Protocol Analysis Set with both baseline and month 18 assessments.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.27"/>
                    <measurement group_id="O2" value="-0.7" spread="1.15"/>
                    <measurement group_id="O3" value="-0.6" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.588</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.351</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Study Product-related Non-serious Adverse Events (Non-SAEs), by System Organ Class</title>
        <time_frame>Throughout the study period, approximately 4 years</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution
Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Study Product-related Non-serious Adverse Events (Non-SAEs), by System Organ Class</title>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood and Lymphatic System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Disorders &amp; Administration Site Conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, Poisoning, and Procedural Complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and Nutrition Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and Connective Tissue Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive System and Breast Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, Thoracic and Mediastinal Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and Subcutaneous Tissue Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Study Product-related Serious Adverse Events (SAEs), by System Organ Class</title>
        <time_frame>Throughout the study period, approximately 4 years</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution
Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Study Product-related Serious Adverse Events (SAEs), by System Organ Class</title>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiac Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Disorders &amp; Administration Site Conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, Thoracic and Mediastinal Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Any Non-serious Adverse Events (Non-SAEs), by System Organ Class</title>
        <description>Related and unrelated non-SAEs</description>
        <time_frame>Throughout the study period, approximately 4 years</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution
Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Any Non-serious Adverse Events (Non-SAEs), by System Organ Class</title>
          <description>Related and unrelated non-SAEs</description>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood and Lymphatic System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear and Labyrinth Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Disorders &amp; Administration Site Conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, Poisoning, and Procedural Complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and Nutrition Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and Connective Tissue Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoplasms, Benign, Malignant and Unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and Urinary Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive System and Breast Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, Thoracic and Mediastinal Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and Subcutaneous Tissue Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Circumstances</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical and Medical Procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Any Serious Adverse Events (SAEs), by System Organ Class</title>
        <description>Related and unrelated SAEs</description>
        <time_frame>Throughout the study period, approximately 4 years</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution
Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Any Serious Adverse Events (SAEs), by System Organ Class</title>
          <description>Related and unrelated SAEs</description>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood and Lymphatic System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear and Labyrinth Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Disorders &amp; Administration Site Conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, Poisoning, and Procedural Complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and Nutrition Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and Connective Tissue Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoplasms, Benign, Malignant and Unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and Urinary Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, Thoracic and Mediastinal Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical and Medical Procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)</title>
        <description>Refers to non-SAEs and/or SAEs occurring during infusion or within 72 hours of completion of infusion (regardless of causality)</description>
        <time_frame>During or within 72 hours of completion of an infusion</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution
Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)</title>
          <description>Refers to non-SAEs and/or SAEs occurring during infusion or within 72 hours of completion of infusion (regardless of causality)</description>
          <population>Safety Analysis Set</population>
          <units>Infusions</units>
          <param>Number</param>
          <units_analyzed>Infusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3883"/>
                <count group_id="O2" value="3954"/>
                <count group_id="O3" value="3691"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396"/>
                    <measurement group_id="O2" value="467"/>
                    <measurement group_id="O3" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)</title>
        <description>Each adverse event (AE) that was considered related to investigational product (IP) was linked to the most recent infusion administered</description>
        <time_frame>Throughout the study period, approximately 4 years</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution
Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)</title>
          <description>Each adverse event (AE) that was considered related to investigational product (IP) was linked to the most recent infusion administered</description>
          <population>Safety Analysis Set</population>
          <units>Infusions</units>
          <param>Number</param>
          <units_analyzed>Infusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3883"/>
                <count group_id="O2" value="3954"/>
                <count group_id="O3" value="3691"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="265"/>
                    <measurement group_id="O3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE)</title>
        <time_frame>Throughout each infusion period</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution
Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE)</title>
          <population>Safety Analysis Set</population>
          <units>Adverse events</units>
          <param>Number</param>
          <units_analyzed>Infusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3883"/>
                <count group_id="O2" value="3954"/>
                <count group_id="O3" value="3691"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (&gt;1.5 g/dL) Between Consecutive Visits</title>
        <time_frame>Throughout the study period, approximately 4 years</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution
Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (&gt;1.5 g/dL) Between Consecutive Visits</title>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing a Clinically Significant Rash</title>
        <description>Participants requiring systemic therapy or discontinuation from further treatment</description>
        <time_frame>Throughout the study period, approximately 4 years</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% 400mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% 200mg/kg</title>
            <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo 2 mL/kg or 4 mL/kg</title>
            <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution
Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing a Clinically Significant Rash</title>
          <description>Participants requiring systemic therapy or discontinuation from further treatment</description>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rash requiring discontinuation from treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash requiring systemic therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period of approximately 4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IGIV, 10% 400mg/kg</title>
          <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 400 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
        </group>
        <group group_id="E2">
          <title>IGIV, 10% 200mg/kg</title>
          <description>Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) : 200 mg/kg bodyweight every 2 weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
        </group>
        <group group_id="E3">
          <title>Placebo 2 mL/kg or 4 mL/kg</title>
          <description>All participants who received the 2 mL/kg or 4 mL/kg placebo solution
Placebo solution: 2 mL/kg or 4 mL/kg : 0.25% human albumin solution infused every 2weeks for 70 weeks
Adverse Events That Occurred During or After Treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Microcytic Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Hearing Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Diaphragmatic Hernia, Obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gallbladder Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Joint Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Muscle Rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pneumothorax Traumatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-Cell Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Colon Cancer Metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Normal Pressure Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Partial Seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Radicular Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Unresponsive To Stimuli</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Vasogenic Cerebral Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder Due To A General Medical Condition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Inguinal Hernia Repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Knee Arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="127"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="135"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="24" subjects_affected="16" subjects_at_risk="127"/>
                <counts group_id="E2" events="23" subjects_affected="11" subjects_at_risk="135"/>
                <counts group_id="E3" events="16" subjects_affected="10" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E2" events="33" subjects_affected="15" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E2" events="35" subjects_affected="13" subjects_at_risk="135"/>
                <counts group_id="E3" events="28" subjects_affected="12" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Infusion Site Extravasation</sub_title>
                <counts group_id="E1" events="32" subjects_affected="23" subjects_at_risk="127"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="135"/>
                <counts group_id="E3" events="30" subjects_affected="21" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="15" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E3" events="21" subjects_affected="15" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="135"/>
                <counts group_id="E3" events="20" subjects_affected="10" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="135"/>
                <counts group_id="E3" events="31" subjects_affected="23" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" events="65" subjects_affected="19" subjects_at_risk="127"/>
                <counts group_id="E2" events="67" subjects_affected="12" subjects_at_risk="135"/>
                <counts group_id="E3" events="49" subjects_affected="9" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="135"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Microhaemorrhage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="127"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="135"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="114" subjects_affected="29" subjects_at_risk="127"/>
                <counts group_id="E2" events="101" subjects_affected="34" subjects_at_risk="135"/>
                <counts group_id="E3" events="65" subjects_affected="22" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="135"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="135"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="135"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="135"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="135"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="135"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="127"/>
                <counts group_id="E2" events="27" subjects_affected="19" subjects_at_risk="135"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="27" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E2" events="27" subjects_affected="18" subjects_at_risk="135"/>
                <counts group_id="E3" events="22" subjects_affected="11" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication (by USCD) or 12 months after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥45 days prior to submission or communication. Baxter may request an additional delay of ≤45 days(e.g., for intellectual property protection)</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Gelmont, MD, Global Medical Director, Head of Specialty Products TA, BioTherapeutics</name_or_title>
      <organization>Baxter Healthcare Corporation</organization>
      <email>david_gelmont@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

